Used primarily in the treatment of hematologic malignancies, particularly acute myeloid leukemia (AML). It functions as a selective inhibitor of spleen tyrosine kinase (Syk), which plays a key role in signaling pathways involved in immune cell activation and survival of malignant B-cells. By blocking Syk, it helps suppress the proliferation and survival of cancer cells. It has been investigated in clinical trials both as a monotherapy and in combination with other agents such as chemotherapy or targeted therapies. Its selectivity may offer a favorable safety profile compared to broader kinase inhibitors, making it a candidate for patients who are not responsive to standard treatments. Research also explores its potential in other B-cell-related malignancies and inflammatory conditions where Syk signaling is dysregulated.